Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03779438
Other study ID # aswu/189/18
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2019
Est. completion date March 1, 2022

Study information

Verified date February 2019
Source Aswan University Hospital
Contact hany f sallam
Phone 01022336052
Email hany.farouk@aswu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa


Description:

Most authors report an increased risk of bleeding with advancing gestation among women with placenta previa.

The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) both recommend the use of 17-OHPC to prevent recurrent spontaneous preterm birth.

Preterm deliveries account for 75% of perinatal mortality and surviving preterm infants are at risk for neurological, respiratory, and gastrointestinal complications. So, it is therefore very important to try to prolong the pregnancy without increasing the risk of emergent delivery in cases with placenta previa. The authors hypothesized that a pharmacological strategy like 17-alpha-Hydroxyprogesterone caproate may improve pregnancy outcomes and may also allow obstetricians to tailor their approach to save delayed scheduled cesarean section women with a placenta previa.

The aim of this study to evaluate the role of17-alpha-Hydroxyprogesterone caproate in the prevention of preterm cesarean delivery (CD) in cases with symptomatic placenta previa with avoids of an emergent CD which affects the maternal outcome and prevents prematurity which affects the prenatal outcome.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date March 1, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Estimated gestational age: between 24 weeks and 37 week's gestation

- Confirmed Placenta previa; either major or minor degrees.

- Placenta previa with preterm uterine contractions or with a history of at least single attack of mild vaginal bleeding

Exclusion Criteria:

- Severe attack of bleeding requiring an immediate intervention.

- Fetal heart rates instability or non-reassuring tracing

- Intrauterine fetal death or major fetal anomalies.

- If associated with abruptio placentae

- Patients with known bleeding disorders or on anticoagulant therapy

- Patients with severe medical disorders

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
17-OHPC
patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
placebo to 17-OHPC
patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery

Locations

Country Name City State
Egypt Aswan University Aswan

Sponsors (1)

Lead Sponsor Collaborator
Aswan University Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary the duration of prolongation of pregnancy from the time of enrollment to the time of delivery measure the duration of prolongation of pregnancy in days measured from the time of enrollment to the time of delivery 6 weeks
Secondary apgar score measure apgar score from 0 to 10 5 minutes postpartum
Secondary the number of patients with postpartum hemorrhage calculation the number of patients with postpartum hemorrhage 24 hours post operative
See also
  Status Clinical Trial Phase
Recruiting NCT04518163 - Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa N/A
Recruiting NCT04518150 - Combined Bilateral Uterine Artery Ligation and Bakri Balloon During Cesarean Section N/A
Recruiting NCT03638024 - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Terminated NCT01996345 - Vaginal Pessary Versus Expectant Management for Placenta Previa N/A
Recruiting NCT04609527 - Management of Placenta Accreta Spectrum Phase 2/Phase 3
Completed NCT03431116 - Low Implanted Second Trimester Placenta and Placenta Previa N/A
Completed NCT03321435 - The Placenta Previa and Fetal Weight N/A
Enrolling by invitation NCT05529381 - Anxiety and Depressive Symptoms in Placenta Previa / Accreta
Completed NCT04264234 - Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria N/A
Completed NCT05340205 - Blood Loss During Cesarean Delivery in Placenta Previa Patients Phase 4
Completed NCT03570723 - Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa N/A
Completed NCT05283122 - Mostafa Maged Technique to Control and Prevent the Post-Partum Bleeding From the Lower Uterine Segment in Placenta Previa Cases N/A
Withdrawn NCT01442207 - Cerclage for Prevention on Preterm Birth in Women With Placenta Previa Phase 3
Not yet recruiting NCT03451136 - Cervical Length in Cases of Placenta Previa N/A
Completed NCT02966197 - Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta N/A
Recruiting NCT02590484 - The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta N/A
Recruiting NCT05802251 - Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study
Completed NCT03542552 - Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa Phase 3
Recruiting NCT03124472 - Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa N/A
Recruiting NCT03633175 - Progesterone in Patients With Placenta Previa Phase 2